A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

被引：0
|
作者：
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, J. Randolph
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn
Cho, Gene
Liganor, Lorna
Cho, Sangsook Ahn
Walker, Evan Justin
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens, San Francisco, CA USA
[3] HonorHealth Res Inst, Scottsdale, AZ USA
[4] Clin Res Alliance, Westbury, NY USA
[5] UCLA, Jonsson Comprehens Canc Ctr, Santa Monica, CA USA
[6] LSU Sch Med, New Orleans, LA USA
[7] Karmanos Canc Inst, Detroit, MI USA
[8] Virginia Canc Specialists VCS Res Inst, Fairfax, VA USA
[9] CG Pharmaceut Inc, Orinda, CA USA
[10] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4206
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
    Nakayama, Goro
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Uehara, Keisuke
    Kojima, Hiroshi
    Ishiyama, Akiharu
    Hayashi, Naomi
    Takano, Nao
    Hattori, Norifumi
    Kobayashi, Daisuke
    Tanaka, Chie
    Hayashi, Masamichi
    Kanda, Mitsuro
    Yamada, Suguru
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    BMC CANCER, 2017, 17
  • [32] The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
    Goro Nakayama
    Kiyoshi Ishigure
    Hiroyuki Yokoyama
    Keisuke Uehara
    Hiroshi Kojima
    Akiharu Ishiyama
    Naomi Hayashi
    Nao Takano
    Norifumi Hattori
    Daisuke Kobayashi
    Chie Tanaka
    Masamichi Hayashi
    Mitsuro Kanda
    Suguru Yamada
    Hiroyuki Sugimoto
    Masahiko Koike
    Michitaka Fujiwara
    Tsutomu Fujii
    Kenta Murotani
    Yuichi Ando
    Yasuhiro Kodera
    BMC Cancer, 17
  • [33] TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
    Javle, Milind M.
    Oh, Do-Youn
    Ikeda, Masafumi
    Qin, Shukui
    Yong, Wei-Peng
    Chao, Yee
    McIntyre, Nicola
    Hsieh, Chih-Yi
    Chow, Lilian
    Chang, Alyssa
    McHale, Mark
    Lindmark, Bertil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
    Kerr, Rachel S.
    Love, Sharon
    Segelov, Eva
    Johnstone, Elaine
    Falcon, Beverly
    Hewett, Peter
    Weaver, Andrew
    Church, David
    Scudder, Claire
    Pearson, Sarah
    Julier, Patrick
    Pezzella, Francesco
    Tomlinson, Ian
    Domingo, Enric
    Kerr, David J.
    LANCET ONCOLOGY, 2016, 17 (11): : 1543 - 1557
  • [35] A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
    O'Reilly, Eileen Mary
    Oh, Do-Youn
    Dhani, Neesha
    Renouf, Daniel John
    Lee, Myung Ah
    Sun, Weijing
    Fisher, George A.
    Hezel, Aram F.
    Chang, Shao-Chun
    Vlahovic, Gordana
    Takahashi, Osamu
    Yang, Yin
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Heloisa P. Soares
    Soley Bayraktar
    Marcelo Blaya
    Gilberto Lopes
    Jaime Merchan
    Jessica Macintyre
    Carlos Mayo
    Mark R. Green
    Orlando Silva
    Joe Levi
    Gail Walker
    Caio M. Rocha-Lima
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 839 - 845
  • [37] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Soares, Heloisa P.
    Bayraktar, Soley
    Blaya, Marcelo
    Lopes, Gilberto
    Merchan, Jaime
    Macintyre, Jessica
    Mayo, Carlos
    Green, Mark R.
    Silva, Orlando
    Levi, Joe
    Walker, Gail
    Rocha-Lima, Caio M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 839 - 845
  • [38] Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial
    Tian, Yuan
    Yang, Peigang
    Guo, Honghai
    Liu, Yang
    Zhang, Ze
    Ding, Pingan
    Zheng, Tao
    Deng, Huiyan
    Ma, Wenqian
    Li, Yong
    Fan, Liqiao
    Zhang, Zhidong
    Wang, Dong
    Zhao, Xuefeng
    Tan, Bibo
    Liu, Yu
    Zhao, Qun
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4000 - 4008
  • [39] First report of the safety/tolerability and preliminary antitumor activity of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer: An open-label, randomized phase Ib/II study
    Li, W.
    Chang, J.
    Wang, C.
    Peng, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S452 - S452
  • [40] Survival analysis of maintenance therapy with capecitabine (Cape) in patients with resected pancreatic adenocarcinoma (PAC) after adjuvant therapy: A retrospective cohort study
    Yang, Xuezhong
    Weinberg, Benjamin
    Hwang, Jimmy J.
    Wu, Christina Sing-Ying
    Akram, Madeeha
    Pishvaian, Michael J.
    He, Aiwu Ruth
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345